TABLE 1.
SVR12 rates by HCV subtype, treatment duration, prior treatment experience, and cirrhosis status in DAA-naive patientsf
| HCV subtypea | SVR12 (%) (no. of patients with response/total no. of patients enrolled) |
|||||
|---|---|---|---|---|---|---|
| Without cirrhosis |
With compensated cirrhosis, 12 wk |
|||||
| 8 wk |
12 wk |
TN | IFN-TE | |||
| TNb | IFN-TEc | TN | IFN-TE | |||
| 1a | 100 (3/3) | 100 (1/1) | X | X | ||
| 1b | 100 (93/93) | 97.1 (34/35)d | X | X | 100 (26/26) | 100 (12/12) |
| 2a | 96.5 (55/57)d | 100 (11/11) | X | X | 100 (4/4) | 100 (6/6) |
| 2b | 100 (21/21) | 100 (6/6) | X | X | 100 (9/9)e | 100 (1/1) |
| 2* | 100 (2/2) | X | X | |||
| 3a | X | X | 100 (3/3) | 100 (3/3) | 100 (1/1) | |
| 3b | X | X | 100 (1/1) | 50.0 (1/2) | 100 (1/1) | |
| 3k | X | X | 0 (0/1) | |||
HCV subtype was determined by phylogenetic analysis of NS3/4A and/or NS5A sequences. In the absence of phylogenetic data (4 treatment-naive GT1b- and 2 treatment-naive GT2*-infected patients), subtype designation was done by LiPA 2.0 assay.
Includes 2 GT1b-infected, 1 GT2a-infected, 2 GT2b-infected, and 2 GT2 (with an undetermined subtype)-infected SVR12-achieving patients with severe renal impairment.
Includes 1 GT1b- and 2 GT2a-infected SVR12-achieving patients with severe renal impairment.
Patients not achieving SVR12 were lost to follow-up or prematurely discontinued treatment.
Includes 2 GT2b-infected SVR12-achieving patients with severe renal impairment.
X indicates that patients with these HCV genotypes were excluded per enrollment criteria. * indicates that the HCV subtype was unable to be determined. IFN-TE, treatment experienced with an interferon-containing regimen but DAA naive; TN, DAA treatment naive.